GENELUX Corp (GNLX): who owns it and who trades it
As of Nov 16, 2026, GNLX insiders reported 25 open-market sales worth $368K and no purchases in the last 12 months, with 30% of the sale value made under pre-set 10b5-1 plans. The largest seller was Thomas Zindrick (CEO), with $148K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling GENELUX
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns GNLX
72 funds and institutions reported GNLX shares worth $29.6M at the end of Q2 2026, about 22% of the company. The largest holder is Woodward Diversified Capital, LLC with 5.0%.
Funds and institutions (13F) 22%Everyone else 78%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Woodward Diversified Capital, LLC | 2.26M | 5.05% | $6.8M | +7% |
| Vanguard Capital Management LLC | 1.68M | 3.74% | $5M | -1% |
| Bleichroeder LP | 1.38M | 3.08% | $4.2M | No change |
| BlackRock, Inc. | 439,602 | 0.98% | $1.3M | +8% |
| Geode Capital Management, LLC | 439,213 | 0.98% | $1.3M | -3% |
| CM Management, LLC | 400,000 | 0.89% | $1.2M | +60% |
| Bank of America Corp | 328,803 | 0.73% | $990K | +2% |
| Vanguard Fiduciary Trust Co | 236,344 | 0.53% | $711K | -6% |
| Flputnam Investment Management Co | 231,405 | 0.52% | $697K | -18% |
| Global Retirement Partners, LLC | 227,854 | 0.51% | $686K | New |
| LPL Financial LLC | 157,857 | 0.35% | $475K | +14% |
| State Street Corp | 145,850 | 0.33% | $439K | No change |
| Provident Wealth Management, LLC | 144,908 | 0.32% | $436K | -7% |
| LifeSteps Financial, Inc. | 121,965 | 0.27% | $367K | +3% |
| Osaic Holdings, Inc. | 121,958 | 0.27% | $367K | +2% |
| Renaissance Technologies LLC | 105,229 | 0.23% | $317K | +763% |
| Northern Trust Corp | 89,279 | 0.20% | $269K | -46% |
| Citadel Advisors LLC | 85,481 | 0.19% | $257K | New |
| Morgan Stanley | 83,543 | 0.19% | $251K | -5% |
| SteelPeak Wealth, LLC | 75,895 | 0.17% | $228K | +25% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, GNLX insiders reported $0 of open-market purchases and $368K of sales. 30% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Joseph Cappello | Chief Technical Officer | Sale | 668 | $2.04 | $1.4K | Form 4 |
| Nov 3, 2026 | Yong Yu | Chief Scientific Officer | Sale | 668 | $2.01 | $1.3K | Form 4 |
| Nov 3, 2026 | Thomas Zindrick | CEO | Sale | 3,089 | $2.05 | $6.3K | Form 4 |
| Aug 31, 2026 | Joseph Cappello | Chief Technical Officer | Sale | 10,257 | $2.74 | $28.1K | Form 4 |
| Aug 31, 2026 | Thomas Zindrick | CEO | Sale | 34,463 | $2.67 | $92K | Form 4 |
| Aug 31, 2026 | Yong Yu | Chief Scientific Officer | Sale | 9,683 | $2.75 | $26.6K | Form 4 |
| Aug 4, 2026 | Yong Yu | Chief Scientific Officer | Sale | 653 | $2.94 | $1.9K | Form 4 |
| Aug 4, 2026 | Joseph Cappello | Chief Technical Officer | Sale | 653 | $2.95 | $1.9K | Form 4 |
| Aug 4, 2026 | Thomas Zindrick | CEO | Sale | 3,023 | $2.95 | $8.9K | Form 4 |
| Jul 1, 2026 | John W Smither | Director | Sale | 12,000 | $2.91 | $34.9K | Form 4 |
| Jun 3, 2026 | Ralph Smalling | Head of Regulatory | Sale | 192 | $2.93 | $563 | Form 4 |
| Jun 1, 2026 | John Thomas | Director | Sale plan | 10,000 | $2.98 | $29.8K | Form 4 |
| May 11, 2026 | Joseph Cappello | Chief Technical Officer | Sale | 605 | $2.97 | $1.8K | Form 4 |
| May 11, 2026 | Thomas Zindrick | CEO | Sale | 2,798 | $2.94 | $8.2K | Form 4 |
| May 11, 2026 | Ralph Smalling | Head of Regulatory | Sale | 270 | $2.98 | $805 | Form 4 |
| Mar 25, 2026 | Ralph Smalling | Head of Regulatory | Sale | 240 | $2.51 | $602 | Form 4 |
| Mar 24, 2026 | Ralph Smalling | Head of Regulatory | Sale | 345 | $2.42 | $835 | Form 4 |
| Mar 24, 2026 | Joseph Cappello | Chief Technical Officer | Sale | 906 | $2.42 | $2.2K | Form 4 |
| Mar 24, 2026 | Thomas Zindrick | CEO | Sale | 3,582 | $2.42 | $8.7K | Form 4 |
| Mar 2, 2026 | John Thomas | Director | Sale plan | 10,000 | $2.90 | $29K | Form 4 |
| Dec 5, 2025 | Ralph Smalling | Head of Regulatory | Sale | 165 | $4.69 | $774 | Form 4 |
| Dec 1, 2025 | John Thomas | Director | Sale plan | 10,000 | $5.00 | $50K | Form 4 |
| Nov 17, 2025 | Thomas Zindrick | CEO | Sale | 4,509 | $5.37 | $24.2K | Form 4 |
| Nov 17, 2025 | Yong Yu | Vice president | Sale | 973 | $5.37 | $5.2K | Form 4 |
| Nov 17, 2025 | Ralph Smalling | Head of Regulatory | Sale | 343 | $5.37 | $1.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Thomas Zindrick | President and CEO | – | $148K | Nov 3, 2026 |
| John Thomas | Director | – | $109K | Jun 1, 2026 |
| Joseph Cappello | Chief Technical Officer | – | $35.4K | Nov 3, 2026 |
| Yong Yu | SVP, Clinical Development | – | $35.1K | Nov 3, 2026 |
| John W Smither | Director | – | $34.9K | Jul 1, 2026 |
| Ralph Smalling | Head of Regulatory | – | $5.4K | Jun 3, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
GNLX short interest
High short interest. 10.0% of GNLX shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 53%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.53M GNLX shares were sold short, 10.0% of the shares outstanding, down 2.4% from the report before. At the average daily volume of 544,594 shares, buying them all back would take about 8.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.53M | 10.01% | -2% | 544,594 | 8.3 |
| Oct 15, 2026 | 4.64M | 10.26% | +6% | 295,509 | 15.7 |
| Sep 30, 2026 | 4.36M | 9.64% | +6% | 213,487 | 20.4 |
| Sep 15, 2026 | 4.10M | 9.05% | +8% | 284,331 | 14.4 |
| Aug 31, 2026 | 3.78M | 8.34% | +7% | 354,595 | 10.7 |
| Aug 14, 2026 | 3.52M | 7.78% | +14% | 416,184 | 8.4 |
| Jul 31, 2026 | 3.08M | 6.88% | -1% | 152,999 | 20.1 |
| Jul 15, 2026 | 3.11M | 6.95% | +4% | 174,004 | 17.9 |
| Jun 30, 2026 | 3.01M | 6.71% | -6% | 234,814 | 12.8 |
| Jun 15, 2026 | 3.18M | 7.11% | +1% | 152,094 | 20.9 |
| May 29, 2026 | 3.14M | 7.00% | +6% | 130,952 | 23.9 |
| May 15, 2026 | 2.96M | 6.60% | -6% | 196,173 | 15.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
GENELUX company events
GENELUX filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Jun 22, 2026.
- Jun 22, 2026VoteReported shareholder vote results. Filing
- Mar 19, 2026AgreementGenelux Corporation entered into a Sales Agreement with TD Securities (USA) LLC, pursuant to which the Company may, from time to time, offer and sell shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $100 million, through TD Cowen, acting… Filing
- Feb 2, 2026AnnouncementShared information with investors. Filing
- Jan 8, 2026AnnouncementGenelux Corporation entered into an underwriting agreement with Lucid Capital Markets, LLC ( the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten offering an aggregate of 6,666,667 shares of the Company’s common stock, par value $0.001 per share, at a price… Filing
- Jan 5, 2026AnnouncementGenelux reported interim results from two ongoing trials evaluating systemic (intravenous) administration of Olvi-Vec in patients with progressive small cell lung cancer and progressive non-small cell lung cancer, respectively, after failure of prior platinum-based regimens. Filing
- Jan 2, 2026LeadershipPaul Scigalla, M.D. resigned as Chief Medical Officer of Genelux Corporation, effective immediately. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
GENELUX financials
Famous investors that hold GNLX
4 of the 50 well-known investors we track reported holding GNLX in their latest 13F filing. The largest position is Jim Simons's, worth $253K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 99,811 | $253K | 0.0% | -5% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 98,578 | $249K | 0.0% | +15% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 20,858 | $52.8K | 0.0% | -11% |
| Israel Englander · Millennium Management | Q3 2026 | 18,065 | $45.7K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named GNLX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 4, 2026 | Aladar Szalay | 13G/A | 6.2% |
| Nov 4, 2026 | Aladar Szalay | 13G/A | 6.2% |
Questions about GENELUX Corp (GNLX) stock
Who owns the most GNLX stock?
The largest reported owner of GENELUX Corp (GNLX) is Woodward Diversified Capital, LLC, with 5.0% of the company. In total, 72 funds and institutions reported holding GNLX at the end of Q2 2026, together about 22% of the shares. See the largest owners.
Are GNLX insiders buying or selling?
In the last 12 months, GNLX insiders reported no open-market purchases and 25 sales worth $368K. The latest trade was on Nov 3, 2026. See every trade.
What is the short interest in GNLX?
As of Oct 30, 2026, 4.53M GNLX shares were sold short, 10.0% of the shares outstanding, down 2.4% from the report before. At the average daily volume of 544,594 shares, buying them all back would take about 8.3 trading days (days to cover). See the history.
Which famous investors hold GNLX?
4 of the 50 well-known investors we track reported GNLX in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $253K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.